Analyzing blood biomarkers in adults with solid cancer
MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
This study is testing how certain blood markers can help doctors understand and manage solid cancers better for adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 5 sites (Bron and 4 other locations) |
| Trial ID | NCT05089747 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between circulating blood biomarkers and various aspects of solid cancer, including diagnosis, treatment efficacy, and disease progression. Participants will undergo blood sampling to analyze microRNA and circulating DNA as part of standard care. The study seeks to enhance understanding of how these biomarkers can inform clinical decisions and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a histopathologically or cytologically diagnosed solid cancer requiring blood sampling.
Not a fit: Patients who do not require blood sampling as part of their standard care or those with severe anemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with solid cancers.
How similar studies have performed: Other studies have shown promise in using liquid biopsies for cancer diagnosis and monitoring, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (\>18y) * Owing a social security insurance * Any solid cancer diagnosed by histopathology or cytology * Patient with blood sampling required as per standard of care * Informed consent signed Exclusion Criteria: * Refusal to participate * No blood sampling required as per standard of care * Hemoglobin \< 7g/dl (\< 9g/dl if respiratory or cardiovascular disease history) * Heterologous blood transfusion in the last 48 hours * Weight under 20 kg
Where this trial is running
Bron and 4 other locations
- Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est — Bron, France (Recruiting)
- Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord — Lyon, France (Recruiting)
- Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite, France (Recruiting)
- Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite, France (Recruiting)
- Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite, France (Recruiting)
Study contacts
- Study coordinator: Sebastian Couraud, MD, PhD
- Email: sebastien.couraud@chu-lyon.fr
- Phone: +33 4 478 864 401
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.